Baricitinib

This medication produced by Lucius Pharmaceuticals, as a JAK inhibitor, demonstrates a relatively balanced performance in terms of efficacy and safety, providing an effective treatment option for the corresponding patient population.

The following is an overview of the basic information about this medication.

Active Ingredient

The main active ingredient is baricitinib, which belongs to the class of Janus kinase inhibitors.

Target Population

It is indicated for adult patients and pediatric patients aged 2 years and older, depending on the type and severity of the disease.

Dosage and Administration

The recommended dose is usually once daily. Doses of 1mg, 2mg, or 4mg may be selected based on the patient's condition, body weight, and renal function. Reference article: Dosage and Administration of Baricitinib

Medication Use in Special Populations

Dose adjustment is required for elderly patients and patients with renal impairment. This medication is contraindicated in pregnant women and lactating women.

Overdosage

No specific toxicity has been reported for overdosage of this medication. It is recommended to monitor for adverse reactions and provide symptomatic treatment.

Storage

This medication does not require special storage conditions; it only needs to be stored in a cool, dry place at room temperature.

Pharmacokinetics

Pharmacokinetic data show that it is rapidly absorbed after oral administration, with a half-life of approximately 12-16 hours, and is mainly excreted through the kidneys.

FDA，2025.01